

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
ABIRATERONE ACETATE 500 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
0.8 ML ADALIMUMAB 100 MG/ML AUTO-INJECTOR [HUMIRA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
ASENAPINE 10 MG SUBLINGUAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
ASENAPINE 2.5 MG SUBLINGUAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
ASENAPINE 5 MG SUBLINGUAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
AZACITIDINE 200 MG ORAL TABLET [ONUREG]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
AZACITIDINE 300 MG ORAL TABLET [ONUREG]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
CALCIUM OXYBATE 234 MG/ML / MAGNESIUM OXYBATE 96 MG/ML / POTASSIUM OXYBATE 130 MG/ML / SODIUM OXYBATE 40 MG/ML ORAL SOLUTION [XYWAV]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
24 HR DILTIAZEM HYDROCHLORIDE 180 MG EXTENDED RELEASE ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
24 HR DILTIAZEM HYDROCHLORIDE 240 MG EXTENDED RELEASE ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
24 HR DILTIAZEM HYDROCHLORIDE 300 MG EXTENDED RELEASE ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
24 HR DILTIAZEM HYDROCHLORIDE 360 MG EXTENDED RELEASE ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
EPOETIN ALFA-EPBX 10000 UNT/ML INJECTABLE SOLUTION [RETACRIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
EPOETIN ALFA-EPBX 20000 UNT/ML INJECTABLE SOLUTION [RETACRIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
ICOSAPENT ETHYL 1000 MG ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
RUFINAMIDE 40 MG/ML ORAL SUSPENSION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021
SOFOSBUVIR 200 MG / VELPATASVIR 50 MG ORAL TABLET [EPCLUSA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 1/25/2021; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2021

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
EFAVIRENZ 600 MG / EMTRICITABINE 200 MG / TENOFOVIR DISOPROXIL FUMARATE 300 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
EFAVIRENZ 600 MG / LAMIVUDINE 300 MG / TENOFOVIR DISOPROXIL FUMARATE 300 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
EFAVIRENZ 400 MG / LAMIVUDINE 300 MG / TENOFOVIR DISOPROXIL FUMARATE 300 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
EMTRICITABINE 200 MG ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
EMTRICITABINE 200 MG / TENOFOVIR DISOPROXIL FUMARATE 300 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
LAPATINIB 250 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
PRALSETINIB 100 MG ORAL CAPSULE [GAVRETO]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
STIRIPENTOL 250 MG ORAL CAPSULE [DIACOMIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
STIRIPENTOL 500 MG ORAL CAPSULE [DIACOMIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
STIRIPENTOL 500 MG POWDER FOR ORAL SUSPENSION [DIACOMIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
STIRIPENTOL 250 MG POWDER FOR ORAL SUSPENSION [DIACOMIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
0.5 ML DULAGLUTIDE 6 MG/ML AUTO-INJECTOR [TRULICITY]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
0.5 ML DULAGLUTIDE 9 MG/ML AUTO-INJECTOR [TRULICITY]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
FLUOROURACIL 5 MG/ML TOPICAL CREAM	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
INSULIN GLARGINE 100 UNT/ML INJECTABLE SOLUTION [SEMGLEE]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
3 ML INSULIN GLARGINE 100 UNT/ML PEN INJECTOR [SEMGLEE]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
0.5 ML NEISSERIA MENINGITIDIS SEROGROUP A CAPSULAR POLYSACCHARIDE TETANUS TOXOID PROTEIN CONJUGATE VACCINE 0.02 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP C CAPSULAR POLYSACCHARIDE TETANUS TOXOID PROTEIN CONJUGATE VACCINE 0.02 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP W-135 CAPSULAR POLYSACCHARIDE TETANUS TOXOID PROTEIN CONJUGATE VACCINE 0.02 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP Y CAPSULAR POLYSACCHARIDE TETANUS TOXOID PROTEIN CONJUGATE VACCINE 0.02 MG/ML INJECTION [MENQUADFI]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
METYROSINE 250 MG ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
MONOMETHYL FUMARATE 95 MG DELAYED RELEASE ORAL CAPSULE [BAFIERTAM]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
SAPROPTERIN DIHYDROCHLORIDE 500 MG POWDER FOR ORAL SOLUTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
SAPROPTERIN DIHYDROCHLORIDE 100 MG POWDER FOR ORAL SOLUTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
SAPROPTERIN DIHYDROCHLORIDE 100 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021
TOBRAMYCIN 75 MG/ML INHALATION SOLUTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2021 FORMULARY REFERENCE FILE ON 12/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2021